Tiny RNA Cluster Revealed as Master Switch Behind Lung Cancer Survival and Immune Evasion

Non-small cell lung cancer remains the deadliest malignancy worldwide, claiming more lives each year than any other form of the disease, and much of that toll stems from late diagnosis, extraordinary molecular diversity, and the stubborn ability of tumor cells to resist therapy. Now, a team of researchers at the University of Bern has uncovered a previously underappreciated molecular coordinator that helps lung squamous cell carcinoma cells survive, proliferate, and shield themselves from the immune system. In a study published in Cancer Cell International, Maryam Abdipourbozorgbaghi and colleagues, jointly supervised by Ramin Radpour and Simon Haefliger, describe how a pair of microRNAs known as miR-105-5p and miR-767-5p, together termed the miR105/767 cluster, acts as a central regulator of apoptosis, cell-cycle progression, and PD-L1 expression in lung squamous cell carcinoma, one of the two major histological subtypes of non-small cell lung cancer.

MicroRNAs are short, non-coding RNA molecules that do not encode proteins themselves but instead fine-tune gene expression after transcription, typically by binding to target messenger RNAs and promoting their degradation or blocking their translation. A single microRNA can regulate dozens or even hundreds of downstream targets, which makes them powerful nodes in the gene regulatory networks that govern cancer initiation, progression, and treatment resistance. Earlier work had already flagged miR-105-5p and miR-767-5p as overexpressed in a subset of non-small cell lung cancer patients, an overexpression that correlated strongly with poor survival and, intriguingly, with reduced benefit from immune checkpoint inhibitor therapy, the class of drugs that has revolutionized treatment for many patients with advanced lung cancer. What remained unclear was precisely what these two microRNAs were doing inside tumor cells to produce such striking clinical associations.

To answer that question, the Bern team took a systematic experimental approach. They manipulated the levels of miR-105-5p and miR-767-5p in lung squamous cell carcinoma cells grown in vitro, both silencing the microRNAs with knockdown techniques and artificially elevating them through overexpression. They then performed RNA sequencing on the modified cells to capture the global transcriptional consequences of these interventions, applied bioinformatic pathway enrichment analyses to identify the biological programs most affected, and used in silico target prediction tools to trace the molecular threads connecting the microRNAs to their downstream effectors. This combination of wet-lab perturbation and computational analysis allowed the researchers to move beyond correlation and begin establishing the functional architecture of the miR105/767 cluster’s influence on tumor cell behavior.

The first major finding concerned cell survival. When the researchers knocked down miR-105-5p and miR-767-5p, the lung cancer cells responded by undergoing increased apoptosis, the controlled self-destruction program that multicellular organisms use to eliminate damaged or dangerous cells. Cancer cells are, in essence, cells that have learned to evade apoptosis, and the new results indicate that the miR105/767 cluster helps them do exactly that. In addition to the surge in programmed cell death, silencing the cluster reduced progression through the G2-M phase of the cell cycle, the stage at which cells prepare for and execute division, and impaired the overall proliferative capacity of the cultures. Taken together, these observations establish the miR105/767 cluster as a pro-survival factor: its presence keeps lung squamous cell carcinoma cells alive and dividing, while its absence pushes them toward death and cell-cycle arrest.

Delving deeper into the transcriptomic data, the team identified a critical downstream mediator of this apoptotic regulation: ASAH2, the gene encoding N-acylsphingosine amidohydrolase 2, a key enzyme in sphingolipid metabolism. Sphingolipids are a family of membrane lipids whose breakdown products, particularly ceramide and sphingosine, are well-known intracellular signals capable of triggering apoptosis, while other sphingolipid metabolites promote survival and proliferation. By modulating ASAH2, the miR105/767 cluster appears to tilt the balance of sphingolipid metabolism in favor of tumor cell survival, providing a mechanistic bridge between a microRNA cluster, a lipid metabolic pathway, and the fundamental decision between life and death inside a cancer cell. This finding adds lung cancer to the growing list of malignancies in which sphingolipid metabolism emerges as a druggable vulnerability.

Perhaps the most clinically provocative result involved the immune system. When the researchers knocked down miR-105-5p, they observed a significant upregulation of CD274, the gene that encodes PD-L1, at both the messenger RNA and protein levels. Conversely, overexpressing miR-105-5p suppressed PD-L1 expression, indicating that this microRNA directly and negatively regulates the principal molecular brake that tumor cells place on T-cell activity. PD-L1 is the target of several widely used immune checkpoint inhibitors, and its expression level on tumor cells is a key determinant of how visible a tumor appears to the immune system and how well patients respond to immunotherapy. The discovery that a single microRNA can tune PD-L1 expression provides a mechanistic explanation for the earlier clinical observation that high miR105/767 levels are associated with reduced benefit from immune checkpoint inhibitor therapy: tumors rich in miR-105-5p may present lower PD-L1 levels, altering the immune landscape in ways that blunt the effectiveness of PD-1 and PD-L1 directed antibodies.

Yet the relationship between miR-105-5p and PD-L1 turned out to be more nuanced than a simple linear pathway. Despite clearly repressing PD-L1, miR-105-5p primarily promoted tumor cell proliferation through mechanisms that were independent of PD-L1, meaning that the microRNA’s growth-enhancing effects do not run through the immune checkpoint axis. This separation of functions suggests that miR-105-5p wears two distinct hats in lung squamous cell carcinoma: one as a cell-intrinsic driver of proliferation and survival, and another as a modulator of the immune interface between tumor and host. Disentangling these two roles will be essential for any therapeutic strategy that seeks to target the microRNA, since blocking its pro-growth activity and manipulating its effect on PD-L1 could have different and potentially independent consequences for patients.

The second member of the cluster, miR-767-5p, displayed a distinct behavioral profile. When overexpressed, it pushed lung cancer cells into a G0 quiescent state, a dormant condition in which cells exit the active cell cycle and temporarily stop proliferating. This quiescence limited cell proliferation in the overexpression experiments, while knocking miR-767-5p down produced the opposite of what one might naively expect from a factor that suppresses growth: the knockdown increased apoptosis and disrupted cell-cycle control. The picture that emerges is of two cooperating microRNAs with complementary but non-identical functions, jointly safeguarding tumor cell fitness by coordinating the decision to die, the decision to divide, and the decision to rest, with each microRNA contributing its own regulatory signature to the overall program.

For clinicians and drug developers, the study positions the miR105/767 cluster as both a prognostic biomarker and a candidate therapeutic target. As a biomarker, measuring the levels of these two microRNAs in tumor tissue could help identify patients whose tumors are primed for survival and relatively resistant to immune checkpoint blockade, informing treatment selection in a disease where immunotherapy works dramatically for some patients and fails completely for others. As a therapeutic target, the cluster’s downstream effectors offer multiple points of intervention: restoring apoptotic sensitivity by modulating ASAH2 and sphingolipid metabolism, or reshaping the PD-L1 regulatory axis to enhance immune recognition. Because microRNAs each touch many targets, direct anti-miRNA drugs carry risks of off-target effects, but the growing toolkit of oligonucleotide therapeutics and the detailed pathway maps produced by studies like this one are steadily converting such risks into manageable engineering problems.

The work, conducted at the Department of Medical Oncology and the Department of BioMedical Research at Bern University Hospital and the University of Bern, was funded by CTU-Forschungs-Grants from Insel Gruppe, the Werner und Hedy Berger-Janser Stiftung, and the Bernische Stiftung für klinische Krebsforschung. The authors note that the study used fully anonymized and publicly available data where applicable, requiring no ethics committee approval, and they declare no competing interests. As an open-access publication, the findings are freely available to researchers worldwide, and the authors emphasize that the early-shared version is citable and carries a permanent digital object identifier while awaiting the final version of record. For a cancer that still kills more people than any other, the identification of a two-microRNA cluster that simultaneously governs cell death, cell division, and immune evasion is a reminder that some of the most consequential players in tumor biology are among the smallest molecules in the cell.

Subject of Research: Functional role of the miR105/767 microRNA cluster in regulating apoptosis, cell-cycle progression, and PD-L1 expression in non-small cell lung cancer

Article Title: The miR105/767 cluster as a coordinator of apoptosis and PD-L1 expression in non-small cell lung cancer

Article References: Abdipourbozorgbaghi, M., Radpour, R., & Haefliger, S. (2026). The miR105/767 cluster as a coordinator of apoptosis and PD-L1 expression in non-small cell lung cancer. Cancer Cell International. https://doi.org/10.1186/s12935-026-04468-z

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04468-z

Keywords: miR105/767 cluster, non-small cell lung cancer, lung squamous cell carcinoma, microRNAs, PD-L1, apoptosis, cell cycle regulation, ASAH2, sphingolipid metabolism, immune checkpoint inhibitors, biomarker, therapeutic target